Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Similar articles for PubMed (Select 17237794)

1.

Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states.

Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, ap Rhys CM, Holm TM, Loeys BL, Ramirez F, Judge DP, Ward CW, Dietz HC.

Nat Med. 2007 Feb;13(2):204-10. Epub 2007 Jan 21. Erratum in: Nat Med. 2007 Apr;13(4):511.

2.

ACE inhibitor bulks up muscle.

Chamberlain JS.

Nat Med. 2007 Feb;13(2):125-6. No abstract available.

PMID:
17290265
3.

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.

Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC.

Science. 2006 Apr 7;312(5770):117-21.

4.

Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.

Gambarin FI, Favalli V, Serio A, Regazzi M, Pasotti M, Klersy C, Dore R, Mannarino S, Viganò M, Odero A, Amato S, Tavazzi L, Arbustini E.

J Cardiovasc Med (Hagerstown). 2009 Apr;10(4):354-62. doi: 10.2459/JCM.0b013e3283232a45.

PMID:
19430350
5.

Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan?

Matt P, Habashi J, Carrel T, Cameron DE, Van Eyk JE, Dietz HC.

J Thorac Cardiovasc Surg. 2008 Feb;135(2):389-94. doi: 10.1016/j.jtcvs.2007.08.047. Review.

PMID:
18242274
6.

Targeting TGF-beta and the extracellular matrix in Marfan's syndrome.

Kalluri R, Han Y.

Dev Cell. 2008 Jul;15(1):1-2. doi: 10.1016/j.devcel.2008.06.005.

7.

miR-29b participates in early aneurysm development in Marfan syndrome.

Merk DR, Chin JT, Dake BA, Maegdefessel L, Miller MO, Kimura N, Tsao PS, Iosef C, Berry GJ, Mohr FW, Spin JM, Alvira CM, Robbins RC, Fischbein MP.

Circ Res. 2012 Jan 20;110(2):312-24. doi: 10.1161/CIRCRESAHA.111.253740. Epub 2011 Nov 23.

8.

Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome.

Cook JR, Clayton NP, Carta L, Galatioto J, Chiu E, Smaldone S, Nelson CA, Cheng SH, Wentworth BM, Ramirez F.

Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):911-7. doi: 10.1161/ATVBAHA.114.305150. Epub 2015 Jan 22.

PMID:
25614286
9.

Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia.

Burks TN, Andres-Mateos E, Marx R, Mejias R, Van Erp C, Simmers JL, Walston JD, Ward CW, Cohn RD.

Sci Transl Med. 2011 May 11;3(82):82ra37. doi: 10.1126/scitranslmed.3002227.

10.

Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy(2J) /dy(2J) mouse.

Elbaz M, Yanay N, Aga-Mizrachi S, Brunschwig Z, Kassis I, Ettinger K, Barak V, Nevo Y.

Ann Neurol. 2012 May;71(5):699-708. doi: 10.1002/ana.22694.

PMID:
22522482
11.

Circulating transforming growth factor-beta in Marfan syndrome.

Matt P, Schoenhoff F, Habashi J, Holm T, Van Erp C, Loch D, Carlson OD, Griswold BF, Fu Q, De Backer J, Loeys B, Huso DL, McDonnell NB, Van Eyk JE, Dietz HC; GenTAC Consortium.

Circulation. 2009 Aug 11;120(6):526-32. doi: 10.1161/CIRCULATIONAHA.108.841981. Epub 2009 Jul 27.

12.

Angiotensin II blockade in Marfan's syndrome.

Jiménez SA, Rosenbloom J.

N Engl J Med. 2008 Oct 16;359(16):1732-3; author reply 1733-4. No abstract available.

PMID:
18927953
13.

Angiotensin II blockade in Marfan's syndrome.

van Dijk FS, Meijers-Heijboer H, Pals G.

N Engl J Med. 2008 Oct 16;359(16):1733; author reply 1733-4. No abstract available.

PMID:
18927954
14.

Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism.

Habashi JP, Doyle JJ, Holm TM, Aziz H, Schoenhoff F, Bedja D, Chen Y, Modiri AN, Judge DP, Dietz HC.

Science. 2011 Apr 15;332(6027):361-5. doi: 10.1126/science.1192152.

15.

Medicine. Old drug, new hope for Marfan syndrome.

Travis J.

Science. 2006 Apr 7;312(5770):36-7. No abstract available.

PMID:
16601163
16.

Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice.

Podowski M, Calvi C, Metzger S, Misono K, Poonyagariyagorn H, Lopez-Mercado A, Ku T, Lauer T, McGrath-Morrow S, Berger A, Cheadle C, Tuder R, Dietz HC, Mitzner W, Wise R, Neptune E.

J Clin Invest. 2012 Jan;122(1):229-40. doi: 10.1172/JCI46215. Epub 2011 Dec 19.

17.

Losartan enhances the success of myoblast transplantation.

Fakhfakh R, Lamarre Y, Skuk D, Tremblay JP.

Cell Transplant. 2012;21(1):139-52. doi: 10.3727/096368911X576045. Epub 2011 Apr 29.

PMID:
21535912
18.

Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial.

Radonic T, de Witte P, Baars MJ, Zwinderman AH, Mulder BJ, Groenink M; COMPARE study group.

Trials. 2010 Jan 12;11:3. doi: 10.1186/1745-6215-11-3.

19.

Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy.

Morine KJ, Bish LT, Selsby JT, Gazzara JA, Pendrak K, Sleeper MM, Barton ER, Lee SJ, Sweeney HL.

Muscle Nerve. 2010 Nov;42(5):722-30. doi: 10.1002/mus.21743.

PMID:
20730876
20.

Recent progress towards a molecular understanding of Marfan syndrome.

Dietz HC, Loeys B, Carta L, Ramirez F.

Am J Med Genet C Semin Med Genet. 2005 Nov 15;139C(1):4-9. Review.

PMID:
16273535
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk